Merseyside Regional Head and Neck Cancer Centre
How will head or neck cancer affect my life

Clinical Trials in Development:

 

Randomised Control Trials:

TITAN:

TITAN is a open-label randomized controlled trial conducted in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC).

Induction(TPF) chemotherapy is a significant recent advance in the management of locally advanced HNSCC, although its use in combination with surgery and postoperative radiotherapy(PORT) is under-researched.

TITAN address the potential survival advantage of TPF induction chemotherapy prior to surgery and radiotherapy for locally advanced resectable SCCHN.

Click here for more information on the Titan Trial.

 


 

REALISTIC:

HPVs are obligate human pathogens, some have the propensity to promote malignant transformations of their host cells. An example of this is HPV-16 in the oropharyngeal squamous cell carcinoma, which is seen in about 50-70% of cases although there is geographical variation.

ADXS11-001 (formerly Lovaxin C) is a bioengineered strain of living Listeria monocytogenes that induces a strong therapeutic immune response using multiple mechanisms of action. This vaccine secretes the tumour antigen HPV-16 E7 fused to an attenuated Lm virulence factor, Listeriolysin O (LLO), which has strong adjuvant properties.

If proved safe, there is a role for ADXS11-001 as a post-treatment adjuvant as part of a treatment de-escalation strategy in an attempt to reduce the adverse effects of current treatment strategies without compromising survival. The REALISTIC trials' objective is to determine safety and to characterise the toxicity profile of ADXS11-001.

Click here for more information on the 'Realistic' trial

 


 

IMCAT:

Phase IIa clinical trial where "Autologous dendritic cells (DCs) isolated and activated by photopheresis and then injected into and around metastatic cervical lymph nodes". Patients undergo two cycles prior to definitive treatment.

 

Click here for more information on the 'IMCAT' trial.

 


 

DAHANCA 21:

DAHANCA 21 is a randomised clinical study of hyperbaric oxygen treatment of mandibular osteoradionecrosis.

Click here for DAHANCA 21 information.Click on the image for more DAHANCA 21 information.

 


 

 

 

 

 

 

 

 

 

 

Click here for 'Cancer Research UK' home page

 

Click here for the 'Liverpool Cancer Trials Unit' home page

 

Click here for the 'Liverpool Experimental Cancer Medicine Centre'

 

Click here for the 'University of Liverpool' 'Head & Neck Oncology Research' page.